Viral and Antiretroviral Dynamics in HIV-1 Mother-to-Child Transmission Fluids

CompletedOBSERVATIONAL
Enrollment

194

Participants

Timeline

Start Date

December 22, 2017

Primary Completion Date

December 31, 2019

Study Completion Date

September 17, 2020

Conditions
Human Immunodeficiency Virus Infection
Interventions
DRUG

Tenofovir Disoproxil Fumarate (TDF) 300 mg + Lamivudine (3TC) 300 mg + Efavirenz (EFV) 600 mg

Fixed-dose combination of 300 mg TDF, 300 mg 3TC and 600 mg EFV taken once daily.

DRUG

Abacavir (ABC) 600 mg + Lamivudine (3TC) 300 mg + Efavirenz (EFV) 600 mg

Fixed-dose combination of 600 mg ABC, 300 mg 3TC and 600 mg EFV taken once daily.

DRUG

Zidovudine (AZT) 300 mg + Lamivudine (3TC) 150 mg twice daily + Efavirenz (EFV) 600 mg once daily

Fixed-dose combination of 300 mg AZT and 150 mg 3TC taken twice daily, plus 600 mg EFV taken once daily.

Trial Locations (4)

Unknown

St. Monica's Hospital, Adikpo

St. Thomas' Hospital, Ihugh

Bishop Murray Medical Centre, Makurdi

Federal Medical Centre, Makurdi

All Listed Sponsors
collaborator

Federal Medical Centre, Makurdi

UNKNOWN

collaborator

University of Liverpool

OTHER

collaborator

University of California, San Diego

OTHER

collaborator

London School of Hygiene and Tropical Medicine

OTHER

lead

Obafemi Awolowo University

OTHER

NCT03284645 - Viral and Antiretroviral Dynamics in HIV-1 Mother-to-Child Transmission Fluids | Biotech Hunter | Biotech Hunter